Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD study
Authors' conclusion
Patients with IIMs are susceptible to severe COVID-19 BIs. Age and immunosuppressive treatments were related to the risk of BIs.
Study context
- Population
- Respondents to the COVAD e-survey on COVID-19 infection and vaccination in 2022; Breakthrough infections (BIs) = COVID-19 ≥14 days after two vaccine doses
- Participants
- 9,449 included responses
- Exposure
- Idiopathic inflammatory myopathies (IIMs) vs other AIRD, nrAID and healthy controls (HCs)
- IIMsn = 1,406
- Outcome
- Prevalence, characteristics and risk factors of COVID-19 BIs in IIMs
Methodological detailsvalidated patient self-reporting e-survey, multivariable Cox regression
- Validated patient self-reporting e-survey
- Multivariable Cox regression
Main finding
As reported in the abstract
BIs
IIMs
12.9%
182 of 1406
- BIs, all respondents: 1447
- 15.3%
- Increasing age, risk factor for BI in IIMs
- HR 0.98 (95% CI 0.97-0.99)
- HCQ use, risk factor for BI in IIMs
- HR 1.81 (95% CI 1.24-2.64)
- SSZ use, risk factor for BI in IIMs
- HR 3.79 (95% CI 1.69-8.42)
Observational data: associations, not effects.
Further findings
Risk factors for severe BI and hospitalization in IIMs
HR
- GC use, risk factor for severe BI
- 3.61 (95% CI 1.09-11.8)
- Non-white ethnicity, risk factor for hospitalization
- 2.61 (95% CI 1.03-6.59)
Safety
Supplemental oxygen therapy
ICU admission
Advanced treatment with antiviral or monoclonal antibodies
Hospitalization
Original publication
Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD study. Rheumatology (Oxford). Published 2 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →